Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Ferdinandos Skoulidis,Kathryn Cecilia Arbour,Matthew D. Hellmann,Pradnya D. Patil,Melina E. Marmarelis,Mark M. Awad,Joseph C. Murray,Jessica A. Hellyer,Justin F. Gainor,Anastasios Dimou,Christine M. Bestvina,Catherine A. Shu,Jonathan W. Riess,Collin M. Blakely,Chad V. Pecot,Laura Mezquita,Fabrizio Tabbò,Matthias Scheffler,Vassiliki A. Papadimitrakopoulou,John V. Heymach

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

2019

102Background: Addition of pembrolizumab (P) to platinum-doublet chemotherapy [carboplatin (or cisplatin) and pemetrexed (CP)] prolongs overall survival and is a standard of care (SOC) for the 1st ...

Keywords:

Cancer research
Pathology
Pembrolizumab
Squamous non-small cell lung cancer
STK11
Medicine
Chemotherapy
non squamous
Carboplatin
Lung cancer
Cisplatin
Internal medicine
Oncology
Pemetrexed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations